News

GSK cancer vaccine disappoints

GSK cancer vaccine disappoints

The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. Photo: Reuters/Luke MacGregor

By Ben Hirschler

LONDON (Reuters) – An experimental cancer vaccine from GlaxoSmithKline failed to help melanoma patients in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project.

Britain’s biggest drugmaker said on Thursday that it would continue with the Phase III trial of its MAGE-A3 therapeutic vaccine to see if it benefited a subset of patients with a particular genetic signature.

The trial has two joint targets, known as co-primary endpoints, looking at both the broad population and a patient subset, so it is possible the treatment will yet prove effective for a small number of people with the deadly skin cancer.

It is also being tested in lung cancer.

The vaccine is one of two particularly high-risk developmental GSK products that industry analysts believe could, in theory, become multi-billion dollar sellers. The other is a heart drug called darapladib, designed to fight clogged arteries in a different way to statins.

In both cases, however, analysts have been wary of modeling firm sales forecasts, given the above-average risk of failure, and as a result GSK stock fell only 1 percent by 1410 GMT.

Shares in its U.S. partner Agenus, however, slumped 33 percent, reflecting the high hopes riding on the project at the small biotech firm. Agenus provides one of the components in GSK’s vaccine.

Citigroup analyst Andrew Baum said that already low consensus expectations for the product are now likely to fall further. He currently forecasts sales of only 149 million pounds ($233 million) in 2018 for the MAGE-A3 vaccine in both melanoma and lung cancer. That figure is about half the industry consensus.

Unlike traditional preventative vaccines, the MAGE-A3 treatment is designed for people with established disease, helping their immune systems to prevent the return of disease after surgery.

Other companies, including Bristol-Myers Squibb, Roche and Merck & Co, have had some recent notable successes in clinical trials of innovative drugs to boost the immune system, but GSK is still pushing the scientific boundaries with its MAGE-A3 vaccine.

DIFFICULT AREA

Cancer vaccines have proved difficult to develop over the years. A different vaccine for lung cancer from Germany’s Merck KGaA also failed in a clinical test last December.

GSK’s vaccine was developed for use in patients with tumors that express the cancer-related MAGE-A3 gene, which occurs in about 65 percent of Stage III melanomas.

It failed to extend disease-free survival significantly when compared with placebo in this population in the Phase III study.

The second endpoint of the trial is to discover whether disease-free survival is improved in a subset of MAGE-A3-positive patients. Results from this analysis are expected in 2015.

GSK added that no safety issues had emerged in the trial.

“We remain committed to identifying a patient sub-population who may benefit from this investigational treatment,” said Vincent Brichard, head of immunotherapeutics at GSK Vaccines.

A spokesman said it was not yet possible to say what proportion of patients might fall into this subset.

GSK is also continuing to study MAGE-A3 in another Phase III study against non-small cell lung cancer. The first data from this trial are expected in the first half of 2014.

Alistair Campbell, of Berenberg Bank, described the chances of a success in lung cancer as “slim”.

“This asset was widely regarded as a ‘wild card’ by the market. While there had been some hope that this approach might work, the result is not a surprise,” he said in a research note.

Roth Captial Partners analyst Joseph Pantginis, who follows Agenus, said he had reduced the projected chance of success for MAGE-A3 in melanoma to 5 percent from 50 percent, with a 15 percent chance of success in lung cancer from 50 percent.

Although the news on melanoma was disappointing, 2013 has still been a strong year so far for GSK research, with new drug approvals in HIV, cancer and respiratory disease.

GSK is now waiting to hear if its latest lung drug, Anoro, will be approved. A U.S. Food and Drug Administration advisory panel is set to assess the medicine on September 10. ($1 = 0.6399 British pounds)

Recent Headlines

in Entertainment

This weekend’s celebrity birthdays

diaz

A look at the celebrities who will be celebrating this weekend.

in Entertainment

WATCH: 10 best ‘Simpsons’ episodes

In this photo released by Fox, Homer explains why he wants to bring back the annual 4th of July fireworks display, after it's cancelled for budget reasons, in the "Yellow Badge of Cowardge" Season Finale episode of "The Simpsons," in May 2014. The full 25-year run of "The Simpsons" will arrive on cable channel FXX with a summer marathon, to be paired this fall with a digital extravaganza that could turn other TV shows yellow with envy. "I'm not going to over-promise, but I think this website will provide you with affordable health care," longtime "Simpsons" executive producer Al Jean told a TV critics' meeting Monday, July 21, 2014.

The recent marathon of all 552 episodes of "The Simpsons" inspired us to sit down and come up with our 10 favorite episodes. Enjoy!

in Music

Robert Plant urges Jimmy Page to give up Led Zeppelin reunion

2012 Kennedy Center Honorees and members of the band Led Zeppelin, from left, Jimmy Page, John Paul Jones, and Robert Plant chat on the red carpet after arriving at the Kennedy Center for the Performing Arts for the 2012 Kennedy Center Honors Performance and Gala Sunday, Dec. 2, 2012 at the State Department in Washington.

Robert Plant has urged his former Led Zeppelin bandmate Jimmy Page to end his war of words with the singer and concentrate on recording new music.

in Entertainment

Lena Dunham and Kate Mara hit by a falling sign

Lena Dunham, of HBO's "Girls," arrives at the 66th Primetime Emmy Awards held at The Nokia Theatre  in Los Angeles.

The "Girls" and "House of Cards" actresses saw stars of their own after an accident at a Venice premiere.

in Entertainment

Charges dropped against Phillip Seymour Hoffman’s suspected drug dealer

In this Jan. 19, 2014 photo, Philip Seymour Hoffman poses for a portrait at The GenArt Quaker Good Energy Lodge during the Sundance Film Festival, in Park City, Utah. Hoffman, who won the Oscar for best actor in 2006 for his portrayal of writer Truman Capote in "Capote," was found dead Sunday, Feb. 2, 2014, in his New York apartment. He was 46.

Drug-selling charges against a friend of late film star Philip Seymour Hoffman have been dropped after officers neglected to read the suspect his Miranda rights.